TYRA - CIK 0001863127
The table below shows Tyra Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $33.47M | $25.47M | $24.31M | $24.96M | $22.70M | $18.00M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| - |
| - |
| - |
| Operating income | -$42.00M | -$32.94M | -$31.45M | -$31.85M | -$28.60M | -$23.53M |
| Income tax | - | - | - | - | - | - |
| Net income | -$39.30M | -$29.87M | -$28.10M | -$28.15M | -$24.02M | -$18.70M |
| EPS (diluted) | -$0.64 | -$0.50 | -$0.47 | -$0.47 | -$0.41 | -$0.32 |